6.3.5. second relapse. rcts reported patients second relapse conventional therapy appears limited effect. patients received two series conventionally dosed therapy (first line first-salvage), hdct autologous stem cell support used although prospect cure < 25% . retrospective data indiana university suggest patients completed hdct may derive additional benefit daily maintenance therapy oral etoposide three months post hdct . prospective evaluation randomised phase ii trial ongoing. patients relapsing within four eight weeks platinum-based therapy, progressing despite platinum-based therapy, well relapsing shortly hdct, considered cisplatin refractory. combinations gemcitabine oxaliplatin triple combination gemcitabine, oxaliplatin paclitaxel resulted response rates 25-45% setting. cisplatin re-challenge association gemcitabine paclitaxel may considered patients adequate renal function . patients second relapse responding combination oxaliplatin gemcitabine triple combination, inclusion clinical trials encouraged. patients good response undergoing subsequent resection residual tumour lesions may still 15-20% chance long-term cure . various targeted agents generally failed refractory disease, including immune checkpoint inhibitors [247-253,257]. trials combining pd1/pdl-1 ctla4 inhibitors ongoing, however, even combinations early results encouraging. 6.3.5.1. late relapse (more two years end first-line treatment) late relapse defined recurrence two years completion successful primary treatment metastatic tc . according pooled analysis, occurs 1.4% 3.2% seminoma non-seminoma patients, respectively . based population-based study, late-relapsing seminoma patients viable gct . treated chemotherapy radiotherapy . contrast, patients late-relapsing nsgct undergo surgical resection feasible, alone combination chemotherapy. patients, including rapidly rising Î²-hcg, may benefit induction salvage chemotherapy subsequent reconsideration surgery resection persisting residual masses . general, however, surgery represents mainstay treatment performed patients feasible irrespective level tumour markers, order completely resect viable gct post-pubertal teratoma [261-265]. survival strongly relates histology recurrent lesions rather initial disease. completely resectable, biopsies obtained histological evaluation direct salvage chemotherapy based tumour phenotype. review experienced pathologist critical avoid misinterpretation therapeutic morphological changes occur treatment gct . patient responds salvage chemotherapy, secondary surgery undertaken feasible. unresectable, localised refractory disease, stereotactic conventional radiotherapy may considered. avoid excess mortality, late relapses treated centres experienced managing patients .